Key result
MMP8 promoter GTTT haplotype linked to ~47% higher hypertension risk across two populations.
Why the study?
MMP8 plays a key role in vascular collagen turnover, but the contribution of regulatory single nucleotide polymorphisms in MMP8 to cardiovascular disease remains unclear.
Does the MMP8 promoter GTTT haplotype increase the risk of hypertension in unrelated individuals?
Case-Control (n=2,565)
Yes
Does the MMP8 promoter GTTT haplotype increase the risk of hypertension in unrelated individuals?
Effect estimate: OR 1.47 (Chennai); OR 1.85 (Chandigarh) (95% CI 1.16-1.86 (Chennai); 1.21-2.81 (Chandigarh))
p-value: p=2x10^-3 (Chennai); 4x10^-3 (Chandigarh)
The MMP8 promoter GTTT haplotype is associated with an increased risk of hypertension, likely due to reduced MMP8 expression during inflammation via diminished NF-κB interaction.
Hypothesis-generating for MMP8 haplotype in hypertension; requires prospective validation before any clinical consideration.
OBJECTIVES: Matrix metalloproteinase 8 (MMP8) has a prominent role in collagen turnover in blood vessels and vascular remodeling. The contribution of regulatory single nucleotide polymorphisms in MMP8 to cardiovascular diseases is unclear. We aimed to delineate the influence of MMP8 promoter variations on hypertension. METHODS: A case-control study in unrelated individuals ( n = 2565) was carried out. Resequencing of the MMP8 proximal promoter, linkage disequilibrium analysis, genotyping of variants and regression analyses were performed. MMP8 promoter-reporter constructs were generated and expressed in human vascular endothelial cells under various conditions. RESULTS: We identified four single nucleotide polymorphisms (SNPs) in the promoter region of MMP8 : -1089A/G (rs17099452), -815G/T (rs17099451), -795C/T (rs11225395), -763A/T (rs35308160); these SNPs form three major haplotypes. Hap3 (viz., GTTT haplotype) carriers showed significant associations with hypertension in two geographically distinct human populations (e.g., Chennai: odds ratio [OR] = 1.47, 95% confidence interval [CI] = 1.16-1.86, P = 2 × 10 -3 ; Chandigarh: OR = 1.85, 95% CI = 1.21-2.81, P = 4 × 10 -3 ). Hap3 carriers also displayed elevated systolic blood pressure, diastolic blood pressure and mean arterial pressure levels. Hap3 promoter-reporter construct showed lower promoter activity than the wild-type (Hap1) construct. In silico analysis and molecular dynamics studies predicted diminished binding of the transcription factor nuclear factor kappa B (NF-κB) to the functional -815T allele of Hap3 compared to the -815G wild-type allele; this prediction was validated by in-vitro experiments. Hap3 displayed impaired response to tumor necrosis factor-alpha treatment, possibly due to weaker binding of NF-κB. Notably, MMP8 promoter haplotypes were identified as independent predictors of plasma MMP8 and endothelial dysfunction markers (von Willebrand factor and endothelin-1) levels. CONCLUSION: MMP8 promoter GTTT haplotype has a functional role in reducing MMP8 expression during inflammation via diminished interaction with NF-κB and in enhancing the risk of hypertension.
No takes yet. Share an insight, caveat, or question.
Maghajothi et al. (2022) conducted a case-control in Hypertension (n=2,565). MMP8 promoter GTTT haplotype (Hap3) vs. Wild-type (Hap1) was evaluated on Hypertension (OR 1.47 (Chennai); OR 1.85 (Chandigarh), 95% CI 1.16-1.86 (Chennai); 1.21-2.81 (Chandigarh), p=2x10^-3 (Chennai); 4x10^-3 (Chandigarh)). The MMP8 promoter GTTT haplotype (Hap3) significantly increased the risk of hypertension in two distinct populations (Chennai: OR 1.47, 95% CI 1.16-1.86; Chandigarh: OR 1.85, 95% CI 1.21-2.81).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: